1190TiP Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)

Patients (pts) with advanced EGFRm NSCLC have limited treatment options after progression with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy (PBC). HER3, a member of the human epidermal growth factor receptor family, is expressed across a variety of solid tumors and in most EGFRm NSCLC. HER3 overexpression has been associated with poor clinical outcomes, including metastatic progression and decreased relapse-free survival. HER3-DXd is a novel antibody-drug conjugate composed of a human anti-HER3 monoclonal antibody (patritumab) linked to a topoisomerase I inhibitor payload via a stable tetrapeptide-based, tumor-selective, cleavable linker.